Regulus TherapeuticsRGLS
RGLS
About: Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Employees: 34
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
245% more call options, than puts
Call options by funds: $38K | Put options by funds: $11K
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
1% less funds holding
Funds holding: 70 [Q3] → 69 (-1) [Q4]
4.96% less ownership
Funds ownership: 86.65% [Q3] → 81.69% (-4.96%) [Q4]
5% less capital invested
Capital invested by funds: $89.1M [Q3] → $84.5M (-$4.54M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
25%
downside
Avg. target
$8.50
7%
upside
High target
$11
38%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Jones Trading Catherine Novack 22% 1-year accuracy 2 / 9 met price target | 12%downside $7 | Hold Downgraded | 30 Apr 2025 |
Canaccord Genuity Whitney Ijem 34% 1-year accuracy 15 / 44 met price target | 38%upside $11 | Hold Downgraded | 30 Apr 2025 |
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target | 25%downside $6 | Overweight Upgraded | 27 Mar 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 25%upside $10 | Buy Reiterated | 14 Mar 2025 |
Financial journalist opinion
Based on 10 articles about RGLS published over the past 30 days
Neutral
PRNewsWire
3 hours ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Regulus Therapeutics Inc. (NASDAQ: RGLS ), relating to the proposed merger with Novartis AG.
Neutral
Benzinga
5 hours ago
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
Positive
Benzinga
6 hours ago
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Neutral
Business Wire
8 hours ago
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareholders. Under the terms of the proposed transaction, Regulus shareholders will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate.
Neutral
Business Wire
9 hours ago
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Regulus will receive only $7.00 per share in cash at closing, or $0.8 billion. In addition.
Positive
Reuters
10 hours ago
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Neutral
GlobeNewsWire
10 hours ago
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease.
Neutral
PRNewsWire
10 hours ago
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion Transaction is expected to be completed in the second half of 2025, subject to customary closing conditions SAN DIEGO , April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus' closing price on April 29, 2025.
Positive
Zacks Investment Research
6 days ago
Should You Buy Regulus (RGLS) After Golden Cross?
Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Neutral
PRNewsWire
4 weeks ago
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
SAN DIEGO , April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9 th at 11:32 a.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
Charts implemented using Lightweight Charts™